OncRef

Clinical Trial: NCT05679895

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:OneChain Immunotherapeutics
Information Provided By:OneChain Immunotherapeutics
Last Update Posted:2026-03-11

Study Overview

Brief Summary

First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)

Official Title

Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL

Conditions

T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma

Intervention / Treatment

  • Biological: CD1a-CAR T

Other Study ID Numbers

  • OC-01-21001

Start Date (Actual)

2023-01-31

Primary Completion Date (Estimated)

2027-12

Study Completion Date (Estimated)

2027-12

Enrollment (Estimated)

20

Study Type

Interventional

Phase

Phase 1